Biocon Biologics in Philippines
Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing.
It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.
Expanding Access to Lifesaving Therapies in APAC
In the Asia-Pacific (APAC) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 7 commercialized biosimilars.
Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the APAC region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia. The company’s integrated insulins manufacturing and R&D facility in Malaysia, the largest in Asia, manufactures a broad portfolio of regular, basal, and rapid-acting insulins.
Focused on Making a Meaningful Difference in Philippines
In the Philippines, Biocon Biologics operates from its office in Bonifacio Global City in Taguig. The company has focused on broadening access to biosimilars for treating cancer through two of its products for the benefit of patients and improving healthcare outcomes in the Philippines since 2018 — Hertraz, which is a biosimilar to Trastuzumab used in the treatment of HER2-positive breast cancer, and Abevmy, a biosimilar to Bevacizumab, which is used in the treatment of various cancers, including colorectal, lung, and kidney cancers.
Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in the Philippines. As a trusted and reliable company, Biocon Biologics is poised to consolidate its leadership in biosimilars in the Philippines, making a meaningful impact on patients’ lives.
Commercialized Products
| Sl. No | Brand Name | Molecule Name | THERAPY AREA |
| 1 | Hertraz | Trastuzumab | Cancer |
| 2 | Abevmy | Bevacizumab | Cancer |
Meet the Leaders
Delivering Highest-Quality Products Globally
80+
03
90+
Our Vision & Values
- Value creation through innovation and differentiation
- Collaboration, teamwork and mutual respect
- Performance-driven work culture
- Quality through compliance and best practices
- Integrity and ethical behaviour
The Biocon Advantage
*19th Annual Report of BioPlan Associates
